Drug Discovery

Peptides
#Artificial intelligence (AI) #Drug discovery #Peptides #Webinar

Webinar: The art and science of cyclic peptide drug design

Cyclic peptides have a special power in the therapeutic space — they’re larger and more specific than small molecules, and more permeable and cost-effective than antibodies. These qualities enable them to conquer two of the biggest challenges in modern drug development: prosecuting flat intracellular protein-protein interactions (PPIs) and achieving oral… Read More

Webinar date:
Supported by BioDuro
#News

#Clinical trials #Drug discovery #MHRA #UK

UK to introduce clinical trial reforms  

New clinical trial regulations are coming into effect this week (28 April) in the UK, with the changes being the largest package of reforms in over 20 years.   Delivered by the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA), the changes will include faster assessment… Read More

#News

Antibody-drug conjugates
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Last chance to register: Overcome the challenges of antibody-drug conjugate development

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar, on 6 May 2026, will demonstrate how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation,… Read More

Webinar date:
Supported by BioDuro
#News

#Drug discovery #GLP-1 #MetaVia #Obesity

What will define the winners in a crowded GLP-1 era? 

HH Kim, CEO and President of MetaVia, asks what the next generation of GLP-1 drugs might look like.  Over the past two decades, only a few biotech sectors have experienced a hype cycle as rapid and publicly frenzied as the obesity drug sector. In just over a year, GLP-1s… Read More

#Exclusive Content

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Drug discovery #eBook #Gene therapy

eBook: Where next for cell & gene therapy?

Cell and gene therapies (CGT) have been transformative for the treatment several diseases, particularly haematological cancers and genetic conditions like sickle cell disease, with many new indications in the pipeline. This eBook, sponsored by Oxford Nanopore Technologies, explores the latest developments in advanced therapies, which treatments are securing industry investment,… Read More

#News

#Drug discovery #Ophthalmology

Web series unpacks the innovation pathway in ophthalmology

Eyecelerator, Unither Pharmaceuticals and Ora have announced the launch of ‘Eye to Market’, a new web series dedicated to accelerating understanding of how ophthalmic innovations move from scientific insight to real-world adoption.   The series will bring together leaders across research, clinical development, manufacturing, and commercialisation to unpack… Read More

#News

AI concept image
#AI #AI / data analytics / healthtech / informatics #Antibodies #Drug discovery

The structural data bottleneck in AI antibody discovery

Dan Benjamin, Co-Founder & Chief Technology Officer of Immuto Scientific, examines why limited antibody–antigen co-structure datasets may be constraining AI model performance—and how high-throughput structural generation could reshape the field. Artificial intelligence now plays a central role in antibody discovery. Machine learning models assist in sequence… Read More

#Exclusive Content

#App note #Bioorthogonal chemistry #Drug discovery #High throughput screening

App Note: What dose-response and orthogonal assays revealed about MEK1 screening

A new App Note is now available to download from Nanotemper. This study highlights the Dianthus uHTS platform for biophysical screening of MEK1, a key kinase in the MAPK/ERK pathway. Using Spectral Shift technology, ~5,120 compounds were profiled in single-dose mode, generating ~250,000 data points per day. Download the… Read More

#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Webinar: Gain insights into ADC biological activity and mechanism-of-action

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar, on 6 May 2026, will demonstrate how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation,… Read More

Webinar date:
Supported by BioDuro
#News

Novo Nordisk head office
#Artificial intelligence (AI) #Collaboration #Drug discovery #Novo Nordisk #OpenAI

Novo Nordisk partners with OpenAI across operations

Novo Nordisk has announced a strategic partnership with OpenAI that it hopes will place the company at the forefront of AI transformation in healthcare and help it bring new and better treatment options to patients faster.  The partnership will apply advanced AI capabilities to analyse complex datasets,… Read More

#Business & Investment #News

Antibody-drug conjugate
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Webinar: Learn how to streamline ADC discovery

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar, available on-demand, will demonstrate how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation, optimised linkers,… Read More

Webinar date:
Supported by BioDuro
#News